Scarica l'app Stockscreener
7.30
2.24%
0.16
Dopo l'orario di chiusura:
7.24
-0.06
-0.82%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché IBRX Giù?
Forum
Previsione
Immunitybio Inc Borsa (IBRX) Ultime notizie
ImmunityBio (IBRX) insider converts $25M note into 4.6M shares - stocktitan.net
IBRX SHAREHOLDER ALERT: Securities Fraud Lawsuit Filed on - GlobeNewswire
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - GlobeNewswire Inc.
ImmunityBio (NASDAQ:IBRX) Trading 2.2% HigherTime to Buy? - MarketBeat
ImmunityBio: No Need To Rush Into Buying TodayWhy I'm Downgrading To Hold (NASDAQ:IBRX) - Seeking Alpha
NASDAQ: IBRX: Kessler Topaz Meltzer & Check, LLP Announces - GlobeNewswire
IMMUNITYBIO, INC. (IBRX) SHAREHOLDER ALERT Bernstein - GlobeNewswire
ImmunityBio Shareholder Alert: ClaimsFiler Reminds - GlobeNewswire
IBRX SHAREHOLDER REMINDER: Faruqi & Faruqi, LLP Reminds ImmunityBio (IBRX) Investors of ... - Bluefield Daily Telegraph
INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in ImmunityBio, Inc. Of Class Action Lawsuit and Upcoming DeadlinesIBRX - PR Newswire
ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman - PR Newswire
Jim Cramer on ImmunityBio: "I would encourage you to own it, provided you don’t own any other spec" - MSN
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit First Filed By the Firm - Morningstar
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. Investors to Secure Counsel Before ... - Bluefield Daily Telegraph
ROSEN, A LEADING LAW FIRM, Encourages ImmunityBio, Inc. - GlobeNewswire
Bronstein, Gewirtz & Grossman LLC Urges ImmunityBio, Inc. Investors to Act: Class Action Filed Alleging Investor Harm - GlobeNewswire
IBRX INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that ImmunityBio, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit! - ACCESS Newswire
IBRX Investor Alert: ImmunityBio Securities Fraud LawsuitInvestors With Losses May Seek to Lead the Class Action After Company Allegedly Violated FDA Drug Rules: Levi & Korsinsky - PR Newswire
IBRX stock notches strongest quarter ever — but these 2 smaller biotech plays ran even hotter - MSN
ImmunityBio (IBRX) Rallies 15% as Firm Raises $100M For Global Expansion - Insider Monkey
IBRX Investors Have Opportunity to Lead ImmunityBio, Inc. Securities Fraud Lawsuit with the Schall Law Firm - Morningstar
IBRX Stock Notches Strongest Quarter Ever — But These 2 Smaller Biotech Plays Ran Even Hotter - Stocktwits
ImmunityBio, Inc. Securities Fraud Class Action Result of FDA Warning and 21% Stock Decline - GlobeNewswire Inc.
10 Stocks Dominating Today’s Market Surge: ImmunityBio, Alkermes, and More - Insider Monkey
Is It Time To Reassess ImmunityBio (IBRX) After Its Recent Volatile Share Price Swings - finance.yahoo.com
Bronstein, Gewirtz & Grossman, LLC Encourages ImmunityBio, Inc. (IBRX) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
ImmunityBio (NASDAQ:IBRX) Shares Up 15.2%What's Next? - MarketBeat
Investors Seek Lead in ImmunityBio Class Action Lawsuit - National Today
Dunkirk pharma plant prepares to hire 100, kick off production - The Business Journals
INVESTOR ALERT: ImmunityBio, Inc. (IBRX) Investors with Substantial Losses Have Opportunity to Lead the ImmunityBio Class Action Lawsuit - PR Newswire
Investors Warned of Large Losses in ImmunityBio Stock - National Today
Why Are ImmunityBio Shares Rising Today? - Benzinga
Jim Cramer on ImmunityBio: “I Would Encourage You to Own It, Provided You Don’t Own Any Other Spec” - Yahoo Finance
Anktiva Gains Ground in Global Cancer Treatment Strategy - StocksToTrade
ImmunityBio strengthens balance sheet to fund Anktiva commercialization - The Pharma Letter
Law Offices of Frank R. Cruz Encourages ImmunityBio, Inc. (IBRX) Shareholders To Inquire About Securities Fraud Class Action - Business Wire
ImmunityBio plunges after getting FDA warning on cancer drug - msn.com
SHAREHOLDER ALERT Bernstein Liebhard LLP Announces A Securities Fraud Class Action Lawsuit Has Been Filed Against ImmunityBio, Inc. (IBRX) - TMX Newsfile
ImmunityBio Inc. (IBRX) Receives FDA Warning Letter Over Cancer Therapy Claims in Advertisement - Insider Monkey
ImmunityBio Secures Major Milestone With ANKTIVA in Asia-Pacific Expansion - timothysykes.com
ImmunityBio Bolsters Balance Sheet With New Financing Moves - TipRanks
IBRX Stock Rises 8% As $100M Financing Boosts Balance Sheet - Stocktwits
ImmunityBio adds $75M under Oberland deal (IBRX:NASDAQ) - Seeking Alpha
IBRX Shareholder Alert: May 26, 2026 Lead Plaintiff Deadline in ImmunityBio, Inc. Securities Class Action Lawsuit — The Gross Law Firm - Morningstar
ImmunityBio stock surges on $100M financing deal - Investing.com
ImmunityBio Secures $75 Million Through Second Amendment to Revenue Interest Agreement - TradingView
ImmunityBio (NASDAQ: IBRX) adds $75M non-dilutive cash and converts $25M debt - stocktitan.net
IMMUNITYBIO, INC. (IBRX) INVESTOR ALERT Investors With - GlobeNewswire
ImmunityBio secures $75M funding, converts $25M debt to equity - Investing.com
ImmunityBio strengthens balance sheet with $100 million of financing transactions including $75 million of non-dilutive financing to support global expansion and advancement of broader immunotherapy pipeline - MarketScreener
Immunitybio Strengthens Balance Sheet With $100 Million Of Financing Transactions Including $75 Million Of Non-Dilutive Financing To Support Global Expansion And Advancement Of Broader Immunotherapy Pipeline - TradingView
ImmunityBio Strengthens Balance Sheet with $100 Million of Financing Transactions Including $75 Million of Non-Dilutive Financing to Support Global Expansion and Advancement of Broader Immunotherapy Pipeline - Business Wire
IBRX Investor Alert: ImmunityBio Securities Fraud Lawsuit – Investors With Losses May Seek to Lead the Class Action After Soon-Shiong Allegedly Overstated ANKTIVA Efficacy: Levi & Korsinsky - TipRanks
FDA Warns Biotech Firm Over Cancer Drug Claims - Infectious Disease Advisor
ImmunityBio Hit with Class Action Lawsuit - National Today
ImmunityBio (NASDAQ:IBRX) Trading Down 9.8%Here's What Happened - MarketBeat
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action ... - Bluefield Daily Telegraph
IMMUNITYBIO CLASS ACTION ALERT: Bragar Eagel & Squire, P.C. - GlobeNewswire
ImmunityBio, Inc. announces completion of a financing transaction totaling 100 million USD, significantly strengthening the company's financial structure. - bitget.com
ImmunityBio, Inc. (IBRX) Faces Securities Class Action Amid FDA Warning Regarding Unsupported Cancer Treatment Claims, $2 Billion Market Capitalization Wiped Out -- Hagens Berman - PR Newswire
ImmunityBio ALERT: $IBRX Investors Who Lost Money Should Contact Block & Leviton By May 26th To Potentially Recover Losses - MarketScreener
Securities Fraud Investigation Into ImmunityBio, Inc. (IBRX) Anno - The National Law Review
ImmunityBio Faces Securities Lawsuit Over Alleged Misleading Statements About Cancer Drug Anktiva - TipRanks
IBRX Class Action Reminder: Robbins LLP Reminds Investors - GlobeNewswire
ImmunityBio’s Tumultuous Week Sees Drastic Stock Tumbles After FDA Warning - StocksToTrade
ImmunityBio Faces Turmoil as Legal Challenges and Misleading Claims Shatter Investor Trust - timothysykes.com
Why is ImmunityBio (IBRX) down 35.8% since last earnings report? - MSN
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):